Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Equity Average (2016 - 2025)

Vanda Pharmaceuticals' Equity Average history spans 14 years, with the latest figure at $498.9 million for Q2 2025.

  • For Q2 2025, Equity Average fell 8.17% year-over-year to $498.9 million; the TTM value through Jun 2025 reached $498.9 million, down 8.17%, while the annual FY2025 figure was $432.9 million, 20.1% down from the prior year.
  • Equity Average for Q2 2025 was $498.9 million at Vanda Pharmaceuticals, down from $525.0 million in the prior quarter.
  • Across five years, Equity Average topped out at $544.5 million in Q1 2024 and bottomed at $460.4 million in Q1 2021.
  • The 5-year median for Equity Average is $516.8 million (2022), against an average of $514.4 million.
  • The largest annual shift saw Equity Average rose 11.9% in 2021 before it dropped 8.17% in 2025.
  • A 5-year view of Equity Average shows it stood at $499.1 million in 2021, then rose by 4.47% to $521.4 million in 2022, then grew by 4.33% to $544.0 million in 2023, then decreased by 0.14% to $543.3 million in 2024, then dropped by 8.17% to $498.9 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Equity Average are $498.9 million (Q2 2025), $525.0 million (Q1 2025), and $543.3 million (Q2 2024).